Thyroid Comprehensive Panel (TSH + fT4 + fT3 + Antibodies)

The Thyroid Comprehensive panel extends the Basic two-marker screen with four additional markers — free T3, anti-TPO, anti-TG, and thyroglobulin — that are necessary to diagnose autoimmune thyroid disease (Hashimoto's thyroiditis, Graves' disease), distinguish thyroid cancer recurrence monitoring, and assess T3/T4 conversion efficiency. Free T3 is the biologically active form of thyroid hormone; its ratio to T4 reveals conversion problems in peripheral tissues. Anti-TPO and anti-TG antibodies are the hallmarks of autoimmune thyroid disease, present in over 90% of Hashimoto's cases. This panel is the appropriate choice when the Basic screen returns borderline results or when autoimmune thyroid disease is suspected.

The Thyroid Comprehensive panel at IFCOR Jihlava provides the complete picture needed to diagnose, classify, and monitor thyroid pathology beyond the capabilities of the Basic two-marker screen. Free T3 (triiodothyronine, the biologically active form) is produced partly by the thyroid and partly by peripheral conversion from T4 in the liver, kidneys, and other tissues. Measuring fT3 alongside fT4 reveals T3/T4 conversion efficiency, which can be impaired in chronic illness, selenium deficiency, or after thyroid surgery — a scenario where TSH and fT4 may appear normal while fT3 is persistently low, causing ongoing symptoms of hypothyroidism. Anti-thyroid peroxidase (anti-TPO) antibodies are immunoglobulins directed against thyroid peroxidase, the enzyme responsible for thyroid hormone synthesis. They are present in more than 90% of patients with Hashimoto's thyroiditis and in approximately 75% of those with Graves' disease. Their measurement is the principal diagnostic tool for autoimmune thyroid disease and allows the physician to predict progression to clinical hypothyroidism in euthyroid individuals with elevated antibodies. Anti-thyroglobulin (anti-TG) antibodies target the thyroid's main structural protein and are found in approximately 60–70% of Hashimoto's cases; they are complementary to anti-TPO, as a minority of autoimmune thyroid disease patients are anti-TPO negative but anti-TG positive. Thyroglobulin itself is used as a tumour marker in differentiated thyroid cancer follow-up — after thyroidectomy, rising thyroglobulin indicates residual or recurrent tumour tissue. The six-marker panel (TSH + fT4 + fT3 + anti-TPO + anti-TG + thyroglobulin) thus covers symptomatic autoimmune screening, conversion efficiency assessment, and oncological monitoring in a single blood draw with results the next business day.